Disturbances in intestinal immunity and other protective mechanisms may have a pivotal role in the cause of certain inflammatory joint diseases. The association between inflammatory bowel disease and arthritis is well established,'
as is the association between intestinal infection with organisms such as yersinia and a reactive seronegative arthritis. Whipple's disease and jejunoileal bypass surgery2 may result in a spondylitis or a reactive arthropathy. These well established associations have prompted research into the relation between disturbances in small intestinal function and inflammatory joint diseases. For example, many patients with ankylosing spondylitis have inflammatory lesions of the terminal ileum,3 and much speculation has centred on the putative association between this condition and intestinal carriage of Klebsiellapneumoniae.' Patients with rheumatoid arthritis and ankylosing spondylitis may have disturbances of small intestinal mucosal permeability, independent of the effect of nonsteroidal anti-inflammatory drugs (NSAIDs).5 Treatment of inflammatory joint diseases may adversely effect the small intestine. Much interest has focused on the effects of NSAIDs on the small intestine, in particular, their effects on small intestinal mucosal permeability. 6 Bjarnason et al have shown that these agents produce inflammatory changes of the small intestine in a significant percentage of patients.7
The notion of an intestinal cause of inflammatory joint diseases is not new. In the 1920s colectomies were performed as a therapeutic measure in patients with rheumatoid arthritis, and Svartz (who first described the treatment of rheumatoid arthritis with sulphasalazine) proposed an enteric cause of this condition in the 1940s. 8 The first part of this review is concerned with immune defences of the small intestine and disturbance of these defences in rheumatic conditions; the second part deals with the intestinal epithelial barrier, mucosal permeability ofthe small intestine, and disturbances of intestinal permeability in rheumatic conditions.
Intestinal immunity and inflammatory joint disease The mucosal surfaces of the body, such as those of the gastrointestinal and respiratory tracts, provide effective barriers to the entry of potentially harmful substances and infectious agents.
Immune and non-immune mechanisms operate to prevent colonisation and invasion by the vast array of potential pathogens to which the secretory mucosae are constantly exposed. It seems that little new light will be shed on the alterations in intestinal immunity in inflammatory arthritis by serum studies. As seen above in our study of intestinal humoral immunity in ankylosing spondylitis, serum antibody response does not always reflect mucosal immunity. Investigators must turn to direct investigation of the intestine if the many questions are to be answered.
Intestinal epithelial barrier, mucosal permeability, prostaglandins, and NSAIDs
The small intestine acts as a selective barrier to material in the gut lumen, allowing absorption of essential nutrients and excluding the rest. If the intestinal mucosa is 'leaky' then potentially antigenic material could gain access to the intestinal lamina propria and the systemic circulation. Possibly, an immune response is thus generated, which may lead to diseases such as inflammatory arthritis. The hypothesis that abnormal intestinal permeability is a primary event in the pathogenesis of inflammatory arthritis has proved attractive and has stimulated much research.
MEASUREMENT OF INTESTINAL PERMEABILITY
Intestinal absorption takes place through both active and passive transport mechanisms; passive absorption takes place through transcellular or paracellular routes. In general, small molecules (such as water) are freely permeable and large molecules (such as dextran) have a low rate of permeability. Medium In summary, therefore, it seems that altered intestinal permeability in rheumatoid arthritis is secondary to NSAID intake, whereas there is convincing evidence that patients with ankylosing spondylitis have altered permeability de novo.
NSAIDs AND THE SMALL INTESTINE
In clinical practice the stomach and duodenum are the most important sites of NSAID induced side effects,53 yet in animal studies it is the small intestine which bears the brunt of NSAID induced damage.54
In humans NSAIDs have been reported to cause small intestinal ulceration,5 inflammation,7 bleeding and perforation,56 and stricture formation.57 Inflammatory bowel disease may be exacerbated or precipitated by these agents,58 and steatorrhoea has been associated with the use of mefenamic acid. 59 Animal models provide some insight into the mechanisms behind NSAID induced damage of the small intestine. A single large dose of indomethacin, given either orally or subcutaneously, causes multiple small intestinal ulcers within 48 hours.54 Ulcers do not occur in germ free animals,' and pretreatment with antibiotics reduces the severity of the damage to the small intestine.6" A reduction in mucosal prostaglandin synthesis may play a central part in the cause of these lesions as the NSAID induced damage is markedly reduced if prostaglandins are given concurrently.62 Del Soldado et al used bigger doses of indomethacin to induce ulcers of the small intestine one to two hours after administration of indomethacin; both prostaglandin E2 and cysteamine (a free radical scavenger) were effective in preventing the erosions, but antibiotics had no beneficial effect. This suggests that reduced mucosal prostaglandins and free radicals are important in the early phase of damage to the small intestine, with the later phase being a result of bacterial overgrowth.
Bjarnason and colleagues have defined the effects ofNSAIDs on the human small intestine.
They used 51Cr-EDTA as a probe molecule to show increased intestinal permeability in patients taking these agents6; this was noted regardless of the type of arthritis for which these agents were taken. They showed that the increase in intestinal permeability was in proportion to 18 months after their discontinuation. Significantly, leucocyte scans were normal in newly diagnosed patients with rheumatoid arthritis-that is, patients not taking NSAIDs; this suggests that inflammation of the small intestine is a manifestation of NSAID use rather than of the inflammatory arthritis itself.
Is NSAID induced inflammation of the small intestine of any clinical significance? Using whole body retention of "SeHCAT and 58Co labelled vitamin B-12 as a marker of ileal dysfunction, Bjarnason et al showed the presence of significant dysfunction in patients taking NSAIDs, but this was not as severe as in Crohn's disease.7 The same group also showed increased intestinal protein loss (using 51Cr labelled proteins) in patients with NSAID induced inflammation. 70 The protein loss was, however, mild, and only one of nine patients studied had hypoalbuminaemia. Inflammation of the small intestine also seems to be associated with blood loss, as shown by the same group using '"Tc labelled red blood cells. The radiolabelled red cells accumulated in the same region as the radiolabelled white cells, suggesting that the inflammation leads to blood loss. The authors suggest that this blood loss associated with inflammation of the small intestine might account for unexplained iron deficiency anaemia commonly seen in arthritic patients.
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